SAN DIEGO and CAMBRIDGE, Mass., June 23 /PRNewswire-FirstCall/--
Biogen, Inc. (Nasdaq: BGEN) and IDEC Pharmaceutical Corporation (Nasdaq: IDPH)
announced that their investor luncheon being held today (June 23) in New York
City will be webcast live at 12:00 pm (EDT). The live webcast is accessible
through the investor relation sections of Biogen (http://www.Biogen.com) and IDEC
Pharmaceuticals (http://www.IDECPharm.com).
(Logo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
About Biogen
Biogen is the world's oldest independent biotechnology company and a
leader in biologics research, development and manufacturing. A pioneer in
leading edge research in immunology, neurobiology and oncology, Biogen brings
novel therapies to improve patients' lives around the world through its global
marketing capabilities.
About IDEC Pharmaceuticals
IDEC is a leader in the discovery, development, and commercialization of
targeted immunotherapies for the treatment of cancer and autoimmune diseases.
IDEC discovered and developed the first commercially available
radioimmunotherapy product (Zevalin) approved in the United States, which is
used to treat certain non-Hodgkin's lymphomas. IDEC also discovered and, with
co-promotion partner Genentech, Inc., developed the first monoclonal antibody
product (Rituxan) approved in the United States for the treatment of cancer.
Rituxan is approved in over 70 countries worldwide and is also used to treat
various types of non-Hodgkin's lymphomas. IDEC is a San Diego-based,
integrated biopharmaceutical company with multiple products in clinical stage
development and strategic alliances in a variety of research platforms.
Contact:
Rob Jacobson
Investor Relations Specialist
Biogen, Inc.
Rob_Jacobson@Biogen.com
617/679-3710
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.IDECPharm.com
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Rob Jacobson, Investor Relations Specialist
of Biogen, Inc., +1-617-679-3710, Rob_Jacobson@Biogen.com
|
